Trader Robot Alchemy: $ZOM's 6.22% Boost Unveiled
In the fast-paced world of stock trading, artificial intelligence (AI) has become a game-changer, and the recent performance of AI trading robots in the "Swing Trader, Popular Stocks: Short Bias Strategy (TA&FA)" is a testament to their effectiveness. Specifically, these bots achieved an impressive +6.22% gain while trading ZOM over the previous week. Let's delve into the technical and fundamental analysis to better understand the factors driving this success.
ZOM's Uptrend:
ZOM has been on a noteworthy uptrend, experiencing a growth of +2.35% over three consecutive days as of December 26, 2023. Traditionally, a three-day upward movement is considered a bullish sign in technical analysis. Historical data indicates that in 188 out of 224 similar instances, the price continued to rise within the following month, suggesting an 84% probability of a sustained upward trend.
Market Cap Overview:
To gain a broader perspective, let's examine ZOM's market capitalization in comparison to the Pharmaceuticals: Other Industry. The average market capitalization within this industry stands at 2.78B, with a range from 246 to 82.08B. Notably, ZTS leads the pack with the highest valuation at 82.08B, while PEMTF holds the lowest valuation at 246.
High and Low Price Movement:
Understanding price movements is crucial for investors. Across all stocks in the Pharmaceuticals: Other Industry, the average weekly price growth is 3%, with a monthly average of 28% and a quarterly average of -5%. Notable mentions include UPC, experiencing the highest weekly growth at 68%, and CHBRF facing the most significant fall at -49%.
Volume Analysis:
Volume is another key indicator in stock analysis. Across all stocks in the Pharmaceuticals: Other Industry, the average weekly volume growth is -32%, with a monthly average of -58% and a quarterly average of 15%. It's essential to note the contrasting trends between price and volume growth, providing valuable insights for traders and investors.
Summary:
The success of AI trading bots in generating a +6.22% gain with ZOM highlights the potential of leveraging technology in stock trading. ZOM's positive uptrend, coupled with insights into market capitalization, price movements, and volume, offers a comprehensive view for investors seeking opportunities in the Pharmaceuticals: Other Industry. As the financial landscape continues to evolve, staying informed and adapting strategies to emerging trends becomes increasingly crucial for successful trading.
ZOM in +2.84% Uptrend, advancing for three consecutive days on October 28, 2024
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ZOM advanced for three days, in of 229 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Aroon Indicator entered an Uptrend today. In of 85 cases where ZOM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 10, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ZOM as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ZOM turned negative on October 14, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
ZOM moved below its 50-day moving average on October 07, 2024 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZOM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ZOM broke above its upper Bollinger Band on October 04, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.526) is normal, around the industry mean (22.821). P/E Ratio (0.000) is within average values for comparable stocks, (83.945). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (5.714) is also within normal values, averaging (42.898).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ZOM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZOM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a company that develops medication for animals
Industry MedicalSpecialties